USFDA: Strides Pharma arm receives USFDA nod for potassium chloride oral solution indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
The
autoimmune hemolytic anemia treatment Market research report thoroughly explains each and every aspect related to the Global autoimmune hemolytic anemia treatment Market, which facilitates the report’s reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.
autoimmune hemolytic anemia treatment Market Insight:
Global Autoimmune hemolytic anemia Treatment Market is growing at a steady CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth
Avail Your Free Sample Copy of the autoimmune hemolytic anemia treatment Market Report (Including Full TOC, List of Tables & Figures, Chart)@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-autoimmune-hemolytic-anemia-treatment-market
Strides Pharma Science arm gets USFDA nod for Ibuprofen OTC Oral Suspension medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.
Strides Pharma Science announced that its
step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received
approval for Ibuprofen Oral Suspension USP,100 mg/5 mL (OTC) from the United States Food &
Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the
Reference Listed Drug (RLD), Children s Motrin Oral Suspension, 100 mg/mL, of Johnson & Johnson
Consumer Inc.
Strides is focusing on building a private label business in the US by leveraging its portfolio of products
across soft gels, tablets, capsules, topicals, powders and oral solutions.
Ibuprofen Oral Suspension
USP,100 mg/5 mL (OTC) further strengthens company s private label portfolio for the US market. According to IRi data, the US market for Ibuprofen Oral Suspension USP,100 mg/5 mL (OTC) is
Strides Pharma Science on Wednesday announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Ibuprofen oral suspension USP, 100 mg/5 mL (OTC) from the United States Food & Drug Administration.The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Children s Motrin oral suspension, 100 mg/mL, of Johnson & Johnson Consumer Inc.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain from various conditions such as headache, dental pain, muscle aches. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu.